26 results
Thumbnail

D2.207 - Early serum IL-6 induction and delayed IL-17A suppression characterise wasp venom allergen-specific immunotherapy

Thumbnail

D2.196 - Elucidating the Immunological Mechanisms of Pollen Immunotherapy in Treating Food Allergy in Patients with Pollen-Food Allergy Syndrome

Thumbnail

D2.197 - Dose-Dependent Immunogenicity and Toxicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy

Thumbnail

D2.198 - Allergen identification and characterization of lysine modification in monomeric allergoid of Olea europea pollen extract

Thumbnail

D2.200 - An interim analysis of a multiCenter study on the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders (CALM study)

Thumbnail

D2.202 - Evaluation of Telemedicine Use in Dietary Advancement Therapy of Cow’s Milk and Egg Allergy: A Retrospective Study

Thumbnail

D2.204 - Allergic potential of plant-derived oils: in vitro murine model of allergies

Thumbnail

D2.205 - Profilin Allergy: Study of the Efficacy and Safety of an Immunotherapy Protocol for the Treatment of Profilin-Related Oral Allergy Syndrome

Thumbnail

D2.206 - Successful treatment of LTP syndrome using allergen immunotherapy: a clinical case

Thumbnail

D2.209 - 'Which bee was it?': A literature review of Honeybee Venom Immunotherapy used in paediatric patients stung by different bee subspecies

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD